136 related articles for article (PubMed ID: 12387303)
21. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
22. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
23. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages.
Tanaka K; Yasuhara M; Suzumura K; Narita H; Suzuki T
Jpn J Pharmacol; 2001 Jul; 86(3):289-96. PubMed ID: 11488428
[TBL] [Abstract][Full Text] [Related]
24. Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions.
Dalla Y; Singh N; Jaggi AS; Singh D
Pharmacol Rep; 2010; 62(5):784-96. PubMed ID: 21098862
[TBL] [Abstract][Full Text] [Related]
25. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
Suzumura K; Kasahara E; Ohnishi Y; Chien KC; Inoue M
Clin Exp Pharmacol Physiol; 2000 Sep; 27(9):709-14. PubMed ID: 10972538
[TBL] [Abstract][Full Text] [Related]
26. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
[TBL] [Abstract][Full Text] [Related]
27. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Atherosclerosis; 2004 Feb; 172(2):259-65. PubMed ID: 15019535
[TBL] [Abstract][Full Text] [Related]
28. Protective effects of apigenin against furan-induced toxicity in mice.
Wang E; Chen F; Hu X; Yuan Y
Food Funct; 2014 Aug; 5(8):1804-12. PubMed ID: 24914499
[TBL] [Abstract][Full Text] [Related]
29. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.
Vandjelovic N; Zhu H; Misra HP; Zimmerman RP; Jia Z; Li Y
Mol Cell Biochem; 2012 May; 364(1-2):71-7. PubMed ID: 22207075
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature.
Shida T; Nozawa T; Sobajima M; Ihori H; Matsuki A; Inoue H
Heart Vessels; 2014 Jul; 29(4):532-41. PubMed ID: 23979266
[TBL] [Abstract][Full Text] [Related]
31. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans.
Nash JD; Burgess DS; Talbert RL
J Med Microbiol; 2002 Feb; 51(2):105-109. PubMed ID: 11863260
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
33. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats.
Işeri S; Ercan F; Gedik N; Yüksel M; Alican I
Toxicology; 2007 Feb; 230(2-3):256-64. PubMed ID: 17196726
[TBL] [Abstract][Full Text] [Related]
34. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction.
Moriyama T; Kawada N; Nagatoya K; Takeji M; Horio M; Ando A; Imai E; Hori M
Kidney Int; 2001 Jun; 59(6):2095-103. PubMed ID: 11380811
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Zhou R; Xu Q; Zheng P; Yan L; Zheng J; Dai G
Eur J Pharmacol; 2008 May; 586(1-3):244-50. PubMed ID: 18384769
[TBL] [Abstract][Full Text] [Related]
37. Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters.
Suzumura K; Ohashi N; Oka K; Yasuhara M; Narita H
Free Radic Res; 2001 Dec; 35(6):815-23. PubMed ID: 11811532
[TBL] [Abstract][Full Text] [Related]
38. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
39. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice.
Suzuki S; Tajima T; Sassa S; Kudo H; Okayasu I; Sakamoto S
Anticancer Res; 2006; 26(6B):4223-8. PubMed ID: 17201137
[TBL] [Abstract][Full Text] [Related]
40. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M
J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
